1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurological Disorder Drugs Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Antipsychotic
1.2.3 Hypnotic & Sedative
1.2.4 Analgesics
1.2.5 Anticoagulants
1.2.6 Others
1.3 Market by Application
1.3.1 Global Neurological Disorder Drugs Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Neurological Disorder Drugs Market Perspective (2017-2028)
2.2 Neurological Disorder Drugs Growth Trends by Region
2.2.1 Neurological Disorder Drugs Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Neurological Disorder Drugs Historic Market Size by Region (2017-2022)
2.2.3 Neurological Disorder Drugs Forecasted Market Size by Region (2023-2028)
2.3 Neurological Disorder Drugs Market Dynamics
2.3.1 Neurological Disorder Drugs Industry Trends
2.3.2 Neurological Disorder Drugs Market Drivers
2.3.3 Neurological Disorder Drugs Market Challenges
2.3.4 Neurological Disorder Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurological Disorder Drugs Players by Revenue
3.1.1 Global Top Neurological Disorder Drugs Players by Revenue (2017-2022)
3.1.2 Global Neurological Disorder Drugs Revenue Market Share by Players (2017-2022)
3.2 Global Neurological Disorder Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neurological Disorder Drugs Revenue
3.4 Global Neurological Disorder Drugs Market Concentration Ratio
3.4.1 Global Neurological Disorder Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurological Disorder Drugs Revenue in 2021
3.5 Neurological Disorder Drugs Key Players Head office and Area Served
3.6 Key Players Neurological Disorder Drugs Product Solution and Service
3.7 Date of Enter into Neurological Disorder Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurological Disorder Drugs Breakdown Data by Type
4.1 Global Neurological Disorder Drugs Historic Market Size by Type (2017-2022)
4.2 Global Neurological Disorder Drugs Forecasted Market Size by Type (2023-2028)
5 Neurological Disorder Drugs Breakdown Data by Application
5.1 Global Neurological Disorder Drugs Historic Market Size by Application (2017-2022)
5.2 Global Neurological Disorder Drugs Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Neurological Disorder Drugs Market Size (2017-2028)
6.2 North America Neurological Disorder Drugs Market Size by Country (2017-2022)
6.3 North America Neurological Disorder Drugs Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Neurological Disorder Drugs Market Size (2017-2028)
7.2 Europe Neurological Disorder Drugs Market Size by Country (2017-2022)
7.3 Europe Neurological Disorder Drugs Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neurological Disorder Drugs Market Size (2017-2028)
8.2 Asia-Pacific Neurological Disorder Drugs Market Size by Country (2017-2022)
8.3 Asia-Pacific Neurological Disorder Drugs Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Neurological Disorder Drugs Market Size (2017-2028)
9.2 Latin America Neurological Disorder Drugs Market Size by Country (2017-2022)
9.3 Latin America Neurological Disorder Drugs Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurological Disorder Drugs Market Size (2017-2028)
10.2 Middle East & Africa Neurological Disorder Drugs Market Size by Country (2017-2022)
10.3 Middle East & Africa Neurological Disorder Drugs Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Detail
11.1.2 Novartis Business Overview
11.1.3 Novartis Neurological Disorder Drugs Introduction
11.1.4 Novartis Revenue in Neurological Disorder Drugs Business (2017-2022)
11.1.5 Novartis Recent Development
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Detail
11.2.2 GlaxoSmithKline Business Overview
11.2.3 GlaxoSmithKline Neurological Disorder Drugs Introduction
11.2.4 GlaxoSmithKline Revenue in Neurological Disorder Drugs Business (2017-2022)
11.2.5 GlaxoSmithKline Recent Development
11.3 Merck & Co.
11.3.1 Merck & Co. Company Detail
11.3.2 Merck & Co. Business Overview
11.3.3 Merck & Co. Neurological Disorder Drugs Introduction
11.3.4 Merck & Co. Revenue in Neurological Disorder Drugs Business (2017-2022)
11.3.5 Merck & Co. Recent Development
11.4 Bayer
11.4.1 Bayer Company Detail
11.4.2 Bayer Business Overview
11.4.3 Bayer Neurological Disorder Drugs Introduction
11.4.4 Bayer Revenue in Neurological Disorder Drugs Business (2017-2022)
11.4.5 Bayer Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Detail
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Neurological Disorder Drugs Introduction
11.5.4 AstraZeneca Revenue in Neurological Disorder Drugs Business (2017-2022)
11.5.5 AstraZeneca Recent Development
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Detail
11.6.2 Boehringer Ingelheim Business Overview
11.6.3 Boehringer Ingelheim Neurological Disorder Drugs Introduction
11.6.4 Boehringer Ingelheim Revenue in Neurological Disorder Drugs Business (2017-2022)
11.6.5 Boehringer Ingelheim Recent Development
11.7 Teva Pharmaceutical
11.7.1 Teva Pharmaceutical Company Detail
11.7.2 Teva Pharmaceutical Business Overview
11.7.3 Teva Pharmaceutical Neurological Disorder Drugs Introduction
11.7.4 Teva Pharmaceutical Revenue in Neurological Disorder Drugs Business (2017-2022)
11.7.5 Teva Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
